Lutikizumab (ABT-981) met its primary end point and all 8 ranked secondary end points in the phase 3 INTREPID trial ...

SPD 2026 highlighted advances in pediatric dermatology spanning textured hair care, vitiligo, vascular anomalies, mental ...

Shannon Trotter, DO, moderated a Dermatology Times Case-Based Roundtable event on how pharmacokinetics, adverse event timing, and trial response criteria should shape hedgehog pathway inhibitor ...

Angela Fitch, MD, co-founder and chief medical officer of Knownwell, discussed GLP-1 access strategies and a proposed ...

This episode, "Efficacy and Safety Data for Emerging Oral HS Agents," has Chao presenting the latest trial results for ...

Dr. Singh presents a 76-year-old woman with a 6-year history of recurrent basal cell carcinoma involving the nasal sidewall ...

In "How Emerging Oral Therapies Target HS Inflammation," the panel explores how JAK and BTK inhibitors interrupt inflammation ...

A young construction worker managed with photoprotection alone continues to have breakthrough phototoxicity and mildly ...

The American Academy of Dermatology (AAD) and Hidradenitis Suppurativa Foundation (HSF) have issued their first joint ...

Galderma announced an agreement to acquire ZO Skin Health for an enterprise value of $1.5 billion, a move designed to expand ...

At Fall Clinical 2026, Joel Gelfand, MD, MSCE, reviewed GLP-1 candidacy, weight conversations, and an upcoming monotherapy ...

Persistence and adherence, not efficacy claims alone, distinguish IL-23 biologics in practice. Real-world claims data reveal ...